A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton’s tyrosine kinase inhibitors (BTKis) single and its combination therapy-Reference-Cited by-同舟云学术

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton’s tyrosine kinase inhibitors (BTKis) single and its combination therapy

Published:2024-03-18 Issue:5 Volume:23 Page:627-636
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Xiang Sichun¹^ORCID,Shen Rongbin¹,Xiang Jingjing¹,Zhu Ni¹,Gu Jianyou¹,Shen Jianping¹,Zhang Yu¹,Ge Hangping¹^ORCID

Affiliation:

1. The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, China

Funder

Special project for the modernization

Zhejiang Provincial Natural Science Foundation

Zhejiang Traditional Medicine and Technology Program for Young Scholar

Specific Program for Young Scholar of Scientific Research

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2024.2327507

Reference21 articles.

1. Targeting B cell receptor signalling in cancer: preclinical and clinical advances

2. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

3. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

4. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

5. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Data mining study on adverse events of tirzepatide based on FAERS database;Expert Opinion on Drug Safety;2024-07-15